Kyverna completes SPS Phase 2 enrollment; BLA filing now 1H 2026; Q1 net loss $44.6M

Kyverna Therapeutics, Inc.

Enrollment completed in KYSA-8 pivotal Phase 2 trial of KYV-101 in stiff person syndrome; topline data 1H 2026.
BLA filing for KYV-101 in SPS accelerated to 1H 2026 (from prior 2026 guidance).
FDA aligns on registrational Phase 3 for myasthenia gravis; interim Phase 2 data expected 2H 2025.
Cash and equivalents $242.6M; runway into 2027 supports first BLA, Phase 3 MG, and pre-launch activities.
Workforce reduced ~16% in Q1 2025; Q1 net loss $44.6M ($1.03/shr) vs $26.7M ($1.12/shr) in Q1 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.